Laboratorios Farmaceuticos Rovi SA
Open
SectorHealthcare
58.25 -0.26
Overview
Share price change
24h
Min
57.95
Max
58.6
Income | -33M 9.5M |
|---|---|
Sales | -66M 152M |
P/E Sector Avg | 24.641 49.052 |
EPS | 0.185 |
Profit margin | 6.216 |
Employees | 1,950 |
EBITDA | -45M 18M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +25.17% upside |
Next Earnings | 23 lip 2026 |
|---|
Market Cap | -1.1B 3B |
|---|---|
Previous open | 58.51 |
Previous close | 58.25 |
News Sentiment
By Acuity
50%
50%
162 / 342 Ranking in Healthcare
Laboratorios Farmaceuticos Rovi SA Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Laboratorios Farmaceuticos Rovi SA
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.